first proved that in patients with metastatic melanomas who were treated with immunotherapy, B2M was lost, suggesting that the loss of B2M might be a possible factor that facilitates cancer cell acquisition of immunotherapy resistance (114). Here, B2M is linked to metastatic melanoma.